FDA Seeks Feedback on Keeping Juice Safe and Clean
Published Date: 2/20/2026
Notice
Summary
The FDA wants to hear from juice makers and importers about their rules for keeping juice safe and clean using special safety checks called HACCP. They’re asking for comments by April 21, 2026, to help decide if they should keep or change these rules. This affects anyone who processes or imports fruit and vegetable juices and helps keep your juice safe without adding extra costs.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Estimated Recordkeeping Time Burden
FDA estimates the annual recordkeeping burden for this collection is 461,426 hours across respondents, covering an estimated 21,980,369 total records. Examples in FDA's estimate include 1,840 recordkeepers producing 95,680 monitoring-related records and activities that together contribute to the total annual hours.
Juice Processors Must Keep HACCP Records
If you process or import fruit or vegetable juices, you must establish and keep Hazard Analysis and Critical Control Point (HACCP) records under 21 CFR part 120. These records document your HACCP plan, monitoring of critical control points, corrective actions, calibration, validation, and revalidation, and must be retained and presented to FDA upon inspection.
Noncompliance Can Trigger Enforcement
If your juice products or records are not in compliance with applicable statutory and regulatory requirements under the FD&C Act, the products may be considered adulterated and subject to FDA enforcement action. FDA uses HACCP records to determine compliance during inspections.
No Capital or O&M Costs Reported
FDA states there are no capital costs or operating and maintenance (O&M) costs associated with this information collection. The agency reports the burden estimate covers time only and lists no monetary capital or O&M expenses.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03331 — Qualification of Drivers; Exemption Applications; Idiopathic Hypersomnia
The FMCSA got a request from someone with idiopathic hypersomnia, a sleep condition, asking to be allowed to drive big trucks across state lines. If approved, this person can keep working while getting medical treatment, but the public has until March 23, 2026, to share their thoughts. This doesn’t change rules for everyone, just this one case, and there’s no cost impact announced.
Next: 2026-03333 — Agency Information Collection Activities; Proposed Collection; Comment Request; Approved Organizations for Wholesale Drug Distributors and Third-Party Logistics Providers
The FDA wants your thoughts on how it collects info about groups that check and license drug wholesalers and delivery companies. This helps keep medicine safe and the supply chain strong. If you’re involved or interested, send your comments by April 21, 2026—no cost to join, just your voice!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in